Abstract
BackgroundPoly(ADP-ribose) polymerase (PARP)facilitates DNA repair and PARP inhibitors may potentiate the effect of DNA-damaging chemotherapeutic agents in patients with cancer. Collection of peripheral blood mononuclear cells (PBMCs)as a surrogate tissue to monitor PARP inhibitor pharmacodynamic effects has several advantages over tumor biopsy collection, including minimally invasive sample collection and the ability to collect multiple samples for longitudinal assessment of drug effect.Methodology/Principal FindingsUsing our previously validated immunoassay for measuring poly(ADP-ribose) (PAR), a product of PARP, in tumor biopsies, we validated a method to quantify PAR levels in PBMCs to monitor the pharmacodynamic effects of the PARP inhibitor ABT-888 in clinical trials. The inter-individual variation in PAR levels was large. No significant difference (P = 0.67) was measured between median baseline PAR levels in 144 healthy volunteers (131.7 pg/1×107 PBMCs [interquartile range, 79.5–241.6]) and 49 patients with cancer (149.2 pg/1×107 PBMCs [interquartile range, 83.2–249.3]). In addition, PAR levels monitored in healthy volunteers over 3 weeks had considerable intra- and inter-individual variation (range, 44–1073 pg PAR/1×107 PBMCs). As a pharmacodynamic model, we quantified changes in PAR levels in human PBMCs treated ex vivo with clinically relevant concentrations of ABT-888. Of 40 healthy volunteer PBMC samples treated with ABT-888, 47.5% had greater than 50% PAR reduction compared to vehicle-treated controls. Considerable inter-sample heterogeneity in PAR levels was measured, and several ABT-888–insensitive samples were identified.Conclusions/SignificanceOur results emphasize the importance of using a validated method to measure PAR levels, and support further investigation into the role of PARP in PBMCs. To this end, the PAR immunoassay has been validated for use with PBMCs and incorporated into clinical trials to assess PBMCs as a potential pharmacodynamic surrogate for tumor biopsies in clinical trials of PARP inhibitors.
Highlights
The National Cancer Institute (NCI) initiated a Phase 0 clinical trial and pharmacodynamic assay program to demonstrate target inhibition of poly(ADP-ribose) polymerase 1 (PARP1) by ABT888, a potent, orally available Poly(ADP-ribose) polymerase (PARP) inhibitor, in tumor biopsies and peripheral blood mononuclear cells (PBMCs) from patients with advanced malignancies [1]
PAR levels were measurable in mouse PBMCs and splenocytes in preliminary studies with a B16–F10 murine melanoma xenograft model, treatment with ABT-888 reduced PAR levels below the assay lower limit of detection
When total protein content for samples with increasing PBMCs/ mL was measured, contamination by plasma proteins resulted in PBMC samples with as few as 0.086107 cells/mL having a total protein content readout equal to that seen in samples with 1.896107 cells/mL (1.20 mg/mL and 1.21 mg/mL protein, respectively; Figure 1B)
Summary
To determine whether ABT-888 would exert a comparable effect on PAR levels in PBMCs as in tumors, we adapted the PAR immunoassay used for tumor tissue [8,10] and validated the method for PBMCs using an ex vivo human PBMC model and standard clinical chemistry methods This assay was subsequently incorporated in early-phase clinical trials of ABT-888 and other PARP inhibitors. Collection of peripheral blood mononuclear cells (PBMCs)as a surrogate tissue to monitor PARP inhibitor pharmacodynamic effects has several advantages over tumor biopsy collection, including minimally invasive sample collection and the ability to collect multiple samples for longitudinal assessment of drug effect
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have